Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Technical Difficulties Prevented Priority Review Of GSK Melanoma Drugs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline withdrew priority review requests for its high-profile melanoma drugs Mekinist and Tafinlar as extensive problems with both the quality of the NDA data and the statistical analysis software in the electronic submissions emerged. Statistical reviewers called out sponsor for inadequate response to problems, wasting time.

Advertisement

Related Content

Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
CDER Approvals In January Came Early And Often

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel